1. Home
  2. MCN vs BNR Comparison

MCN vs BNR Comparison

Compare MCN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Madison Covered Call & Equity Strategy Fund

MCN

Madison Covered Call & Equity Strategy Fund

N/A

Current Price

$5.73

Market Cap

118.4M

Sector

N/A

ML Signal

N/A

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$9.58

Market Cap

99.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MCN
BNR
Founded
2004
2014
Country
Canada
China
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.4M
99.7M
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
MCN
BNR
Price
$5.73
$9.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
51.5K
5.8K
Earning Date
01-01-0001
06-05-2026
Dividend Yield
9.96%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.46
$6.79
52 Week High
$6.39
$41.72

Technical Indicators

Market Signals
Indicator
MCN
BNR
Relative Strength Index (RSI) 67.03 45.70
Support Level $5.66 $8.83
Resistance Level $6.02 $10.72
Average True Range (ATR) 0.05 0.75
MACD 0.01 -0.04
Stochastic Oscillator 100.00 15.47

Price Performance

Historical Comparison
MCN
BNR

About MCN Madison Covered Call & Equity Strategy Fund

XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: